1098340-27-2

Basic information

• Product Name: Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate
• Synonyms: Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate
• CAS NO: 1098340-27-2
• Molecular Formula: C11H8F3NO2
• Molecular Weight: 243.1819296
• Mol File: 1098340-27-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate(1098340-27-2)
• EPA Substance Registry System: Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate(1098340-27-2)

Safety Data

• Hazardous Substances Data: 1098340-27-2(Hazardous Substances Data)

Usage

General Description

Methyl 4-(trifluoromethyl)-1H-indole-2-carboxylate is a chemical compound with the molecular formula C12H8F3NO2. It is organic compound that belongs to the indole family. Indoles are aromatic heterocyclic compounds that can perform various chemical reactions. This particular compound has a trifluoromethyl group, which can improve biological activity in pharmaceuticals and represents a key structural motif in medicinal chemistry. It also has a carboxylate group, which is a strong donor of resonance in chemical structures, potentially further enhancing its reactivity and utility in chemical synthesis. The specific applications and toxicity of this compound are dependent on further research.

Upstream product

• 1362860-87-4 methyl 2-azido-3-(2-(trifluoromethyl)phenyl)acrylate 
• 447-61-0 2-Trifluoromethylbenzaldehyde 

Downstream Products

• 1362861-14-0 methyl 3-(2,5-bis(methoxymethoxy)phenyl)-4-(trifluoromethyl)-1H-indole-2-carboxylate 
• 317-59-9 4-(trifluoromethyl)-1H-indole-2-carboxylic acid 

Relevant articles and documents

Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: A novel DYRK1A inhibitor class

A library of substituted chromeno[3,4-b]indoles was developed as Lamellarin isosters. Synthesis was achieved from indoles after a four-step pathway sequence involving C-3 iodination, a Suzuki cross-coupling reaction, and a one pot deprotection/lactonisation step. Twenty final compounds were tested in order to determine their activity against topoisomerase I and kinases, the two major biological activities of Lamellarins. One newly synthesized derivative exhibited a strong topoisomerase activity comparable to reference compounds such as campthotecin and Lamellarin with only a weak kinase inhibition. Two other lead compounds were identified as new nanomolar DYRK1A inhibitors and several other drugs affected the kinases in the sub-micromolar range. These results will enable us to use the chromeno[3,4-b]indole as a pharmacophore to develop potent treatments for neurological or oncological disorders in which DYRK1A is fully involved.